共 53 条
[1]
Treatment and survival of patients with cancer of the prostate, Surg. Gynecol. Obstet., 124, pp. 1011-1017, (1967)
[2]
Robinson M.R.G., Cancer of the prostate: hormonal therapy, Clin. Oncol., 1, pp. 233-244, (1982)
[3]
Neumann F., Jacobi G.H., Antiandrogens in tumour therapy, Clin. Oncol., 1, (1982)
[4]
Dutta A.S., Furr B.J.A., Luteinizing hormone releasing hormone (LHRH) analogues, Annu. Rep. Med. Chem., 20, pp. 203-214, (1985)
[5]
Furr B.J.A., Milsted R.A.V., LH‐RH analogues in cancer treatment, Endocrine Management of Cancer. 2. Contemporary Therapy, pp. 16-29, (1988)
[6]
Debruyne F.M.J., del Moral P.F., Geboers A.D.H., LHRH analogues therapy for metastatic prostate cancer, Prog. Clin. Biol. Res., 260, pp. 27-39, (1988)
[7]
Furr B.J.A., Hutchinson F., Biodegradable sustained release formulation of the LH‐RH analogue ‘Zoladex’ for the treatment of hormone‐responsive tumours, EORTC Genitourinary Group Monograph 2, Part A. Therapeutic Principles in Metastatic Prostatic Cancer, pp. 143-153, (1985)
[8]
Crawford E.D., Nabors W., Hormone therapy of advanced prostate cancer: where we stand today, Prim. Care Cancer, 11, pp. 13-20, (1991)
[9]
Janknegt R.A., Abbou C.C., Bartoletti R., Bernstein-Hahn L., Bracken B., Brisset J.M., Calais DaSilva F., Chisolm G., Crawford E.D., Debruyne F.M.J., Dijkman G.D., Frick J., Goedhals L., Knonagel H., Venner P.M., Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double‐blind randomized trial, J. Urol., 149, pp. 77-83, (1993)
[10]
Denis L., Murphy G.P., Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer, Cancer, 72, pp. 3888-3895, (1993)